American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis

Hahn, Bevra H.; McMahon, Maureen; Wilkinson, Alan H.; Wallace, W. Dean; Daikh, David I.; Fitzgerald, John; Karpouzas, George; Merrill, Joan T.; Wallace, Daniel J.; Yazdany, Jinoos; Ramsey‐Goldman, Rosalind; Singh, Karandeep; Khalighi, Mazdak A.; Choi, Soo In; Gogia, Maneesh; Kafaja, Suzanne; Kamgar, Mohammad; Lau, Christine; Martin, William J.; Parikh, Sefali; Peng, James; Rastogi, Anjay; Chen, Weiling; Grossman, Jennifer M.

doi:10.1002/acr.21664

Cited by 1,257 publications

(1,181 citation statements)

References 78 publications

Supporting

Mentioning

1,026

Contrasting

Unclassified

Order By: Relevance

“…For the induction therapy of active proliferative LN, both MMF and CYC are suggested as immunosuppressant agents of first choice in recently published guidelines and recommendations [1][2][3][4]. However, according to some guidelines/recommendations, CYC rather than MMF is ''preferable'' for the treatment of severe LN [2,3].…”

Section: Discussionmentioning

confidence: 99%

“…Based on the results of several randomized controlled trials in the last decade, recent guidelines and recommendations have identified mycophenolate mofetil (MMF) and cyclophosphamide (CYC) as the immunosuppressive agents of first choice for the induction or initial therapy of active proliferative LN (class III or IV) [1][2][3][4]. On the other hand, the treatment of severe crescentic LN still remains controversial, although CYC is widely used despite the lack of firm evidence [5].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Successful treatment of severe crescentic lupus nephritis by multi-target therapy using tacrolimus and mycophenolate mofetil

et al. 2014

View full text Add to dashboard Cite

Treatment of severe lupus nephritis (LN) has been controversial, and according to recent guidelines and recommendations, cyclophosphamide still remains a firstline therapy. Herein, we present the case of a 37-year-old female patient who developed rapidly progressive glomerulonephritis, which was histologically diagnosed as class IV ? V LN, with a large number of cellular to fibrocellular crescents (62 % of glomeruli). Although the patient was considered to have the most severe form of LN, complete remission was achieved within 6 months by multi-target therapy using tacrolimus and mycophenolate mofetil combined with methylprednisolone pulse therapy. Our experience suggests that multi-target therapy could be a potential treatment option for patients with severe crescentic LN.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Successful treatment of severe crescentic lupus nephritis by multi-target therapy using tacrolimus and mycophenolate mofetil

et al. 2014

View full text Add to dashboard Cite

show abstract

“…The less severe sideeffect profile of MMF has made it an attractive alternative therapeutic option, but long-term follow-up studies are needed [12]. The 2012 American College of Rheumatology Clinical Practice Guidelines for Lupus Nephritis established MMF as the preferred induction agent compared to CPO for patients in whom fertility preservation (FP) is a major consideration [13]. While the role of CPO in LN therapy may be evolving, at the present time it continues to be an important drug in induction therapy for severe renal disease.…”

Section: Introductionmentioning

confidence: 99%

Fertility preservation in patients receiving cyclophosphamide therapy for renal disease

et al. 2014

View full text Add to dashboard Cite

Cyclophosphamide continues to have an important role in the treatment of renal disease, including nephrotic syndrome and lupus nephritis, despite known complications of gonadotoxicity and potential infertility in both male and female patients. It is important that the physician recommending this therapy mitigates the effect of the drug on fertility by adhering to recommendations on dosing limits and offering fertility-preserving strategies. In addition to wellestablished methods, such as sperm banking and embryo cryopreservation, advances in reproductive technology have yielded strategies such as oocyte cryopreservation, resulting in more fertility-preserving options for the pediatric patient. Despite these advances, there continues to be a significant barrier to referral and access to sperm banks and fertility specialists. These issues are further complicated by ethical issues associated with the treatment of pediatric patients. In this review we explore the development of recommended dosing limits and include a discussion of the available fertility-preserving methods, strategies for increasing access to fertility specialists, and the ethical considerations facing the pediatric healthcare provider.

show abstract

“…Studies using the same assessment tests (1,3), but different dysfunction criteria (1 SD below the norm on 4 of 16 versus 5 of 16 tests), showed highly dissimilar cognitive impairment rates (31% versus 10%). Studies such as the one by Hanley and colleagues (4) that used other assessment tools (i.e., computerized tests) and dysfunction criteria (1.5 SDs below the norm on 4 of 10 tests with different adjustment for sensorimotor speed) reported even lower rates of cognitive impairment (9%).…”

mentioning

confidence: 98%

“…We read with great interest the article on cognitive impairment in rheumatoid arthritis (RA) published recently in Arthritis Care & Research (1). The authors reported on a comprehensive cognitive assessment of 115 patients with RA and noted cognitive impairment in 31% of the participants.…”

mentioning

confidence: 99%

Reply

Katz

Shin

Wallhagen

2013

Arthritis Care & Research

View full text Add to dashboard Cite

American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis

Cited by 1,257 publications

References 78 publications

Successful treatment of severe crescentic lupus nephritis by multi-target therapy using tacrolimus and mycophenolate mofetil

Successful treatment of severe crescentic lupus nephritis by multi-target therapy using tacrolimus and mycophenolate mofetil

Fertility preservation in patients receiving cyclophosphamide therapy for renal disease

Reply

Contact Info

Product

Resources

About